
GILD
GILEAD SCIENCES, INC.
Gilead Sciences develops medicines for viral diseases, cancer and inflammatory conditions.
Company website ↗Upcoming catalysts
Next 30 days- Dec 12, 2026Anito-cel — fourth-line or later multiple myelomaCompany source ↗
Phase 2 data
- GEM-AnitoFIRST early results on December 12, 2026Anito-cel — GEM-AnitoFIRSTCompany source ↗
Phase 2 data
- Dec 12, 2026Yescarta (axicabtagene ciloleucel)Company source ↗
Data readout
View 15 more events
- Dec 12, 2026Yescarta (axicabtagene ciloleucel)Company source ↗
Phase 2 data
- Dec 12, 2026Yescarta (axicabtagene ciloleucel)Company source ↗
Data readout
- Dec 12, 2026Yescarta (axicabtagene ciloleucel)Company source ↗
Data readout
- Dec 13, 2026Anito-cel — fourth-line or later multiple myelomaCompany source ↗
Data readout
- Dec 13, 2026Anito-cel — fourth-line or later multiple myelomaCompany source ↗
Data readout
- December 13, 2026 — bridging irradiation before axi-cel presentationYescarta (axicabtagene ciloleucel)Company source ↗
Conference presentation
- Dec 13, 2026Yescarta (axicabtagene ciloleucel)Company source ↗
Phase 1 data
- Dec 13, 2026om336Company source ↗
Phase 1 data
- December 14, 2026 — GELTAMO LATE-R second interim analysisYescarta (axicabtagene ciloleucel)Company source ↗
Phase 2 data
- Dec 14, 2026KITE-753Company source ↗
Phase 1 data
- Dec 14, 2026Tecartus (brexucabtagene autoleucel)Company source ↗
Conference presentation
- ASH 2026, December 12–15; session date unspecifiedYescarta (axicabtagene ciloleucel)Company source ↗
Data readout
- Second CD19-directed CAR T-cell outcomes at ASH 2026, December 12–15Tecartus (brexucabtagene autoleucel)Company source ↗
Data readout
- Rocca consortium CML analysis at ASH 2026, December 12–15Tecartus (brexucabtagene autoleucel)Company source ↗
Data readout
- Extramedullary B-ALL analysis at ASH 2026, December 12–15Tecartus (brexucabtagene autoleucel)Company source ↗
Data readout